Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
20.67 USD | -0.67% | -11.74% | -10.56% |
Mar. 18 | EyePoint Pharmaceuticals, Inc.(NasdaqGM:EYPT) added to S&P Pharmaceuticals Select Industry Index | CI |
Mar. 07 | Sector Update: Health Care Stocks Mixed Pre-Bell Thursday | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- Low profitability weakens the company.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-10.56% | 1.04B | C+ | ||
+33.46% | 701B | C+ | ||
+26.24% | 571B | B | ||
+0.93% | 381B | C+ | ||
+21.03% | 334B | B- | ||
+17.51% | 319B | C+ | ||
+0.74% | 210B | B+ | ||
+2.95% | 210B | B- | ||
-6.05% | 201B | A+ | ||
-3.61% | 157B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock
- Equities
- Stock EyePoint Pharmaceuticals, Inc. - Nasdaq
- Ratings EyePoint Pharmaceuticals, Inc.